11174 related articles for article (PubMed ID: 11544832)
1. [A novel immunoregulating hexapeptide with antineoplastic effect].
Treshchalina EM; Sedakova LA; Vlasenkova NK; Zhukova OS; Firsova GA; Mikhaĭlova LM; Kolesnikova EIu; Zimakova NI; Khabarov SV; Gerasimova GK
Vopr Onkol; 2001; 47(3):321-7. PubMed ID: 11544832
[TBL] [Abstract][Full Text] [Related]
2. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Guo QL; Wu MS; Chen Z
Acta Pharmacol Sin; 2002 Oct; 23(10):946-51. PubMed ID: 12370101
[TBL] [Abstract][Full Text] [Related]
3. Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery?
Darro F; Decaestecker C; Gaussin JF; Mortier S; Van Ginckel R; Kiss R
Int J Oncol; 2005 Sep; 27(3):607-16. PubMed ID: 16077908
[TBL] [Abstract][Full Text] [Related]
4. [Anti-tumor effect of hernandezine and other components extracted from Thalictrum glandulosissimum].
Xu CX; Lin L; Sun RH; Liu X; Han R
Yao Xue Xue Bao; 1990; 25(5):330-5. PubMed ID: 2284950
[TBL] [Abstract][Full Text] [Related]
5. Effect of testosterone on growth of P388 leukemia cell line in vivo and in vitro. Distribution of peripheral blood T lymphocytes and cell cycle progression.
Aboudkhil S; Henry L; Zaid A; Bureau JP
Neoplasma; 2004; 51(5):368-74. PubMed ID: 15640941
[TBL] [Abstract][Full Text] [Related]
6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of avermectins.
Drinyaev VA; Mosin VA; Kruglyak EB; Novik TS; Sterlina TS; Ermakova NV; Kublik LN; Levitman MKh; Shaposhnikova VV; Korystov YN
Eur J Pharmacol; 2004 Oct; 501(1-3):19-23. PubMed ID: 15464058
[TBL] [Abstract][Full Text] [Related]
10. Genotoxic, cytostatic, antineoplastic and apoptotic effects of newly synthesized antitumour steroidal esters.
Karapidaki I; Bakopoulou A; Papageorgiou A; Iakovidou Z; Mioglou E; Nikolaropoulos S; Mourelatos D; Lialiaris T
Mutat Res; 2009 Apr; 675(1-2):51-9. PubMed ID: 19386248
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
12. Anticancer efficacy of Magainin2 and analogue peptides.
Baker MA; Maloy WL; Zasloff M; Jacob LS
Cancer Res; 1993 Jul; 53(13):3052-7. PubMed ID: 8319212
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of cytotropic heterogeneous molecular lipids (CHML) on human breast cancer xenograft in nude mice.
Zhan Q; Zhao SC; Xu Z
Anticancer Res; 2001; 21(4A):2477-82. PubMed ID: 11724310
[TBL] [Abstract][Full Text] [Related]
14. Application-dependent immunomodulating and antimetastatic efficacy of thymic peptides in BALB/c-mice.
Beuth J; Schierholz JM; Ko HL; Braun JM
In Vivo; 2001; 15(5):403-6. PubMed ID: 11695237
[TBL] [Abstract][Full Text] [Related]
15. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
[TBL] [Abstract][Full Text] [Related]
16. Modification of tumor cell sensitivity to antineoplastic agents lonidamine and bouvardin (NSC 259968) at elevated temperatures.
Adwankar MK; Chitnis MP
Neoplasma; 1986; 33(2):217-23. PubMed ID: 3713924
[TBL] [Abstract][Full Text] [Related]
17. [Endogenous immunoregulatory peptides (myelopeptides): structure, function, and mechanism of action].
Petrov RV; Mikhaĭlova AA; Fonina LA
Bioorg Khim; 1999 Nov; 25(11):811-5. PubMed ID: 10645485
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.
Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G
Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470
[TBL] [Abstract][Full Text] [Related]
19. Effect of testosterone on growth of P388 leukemia cell line in vivo and in vitro. Distribution of peripheral blood T lymphocytes and cell cycle progression.
Aboudkhil S; Henry L; Zaid A; Bureau JP
Neoplasma; 2005; 52(3):260-6. PubMed ID: 15875090
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
Studeny M; Marini FC; Dembinski JL; Zompetta C; Cabreira-Hansen M; Bekele BN; Champlin RE; Andreeff M
J Natl Cancer Inst; 2004 Nov; 96(21):1593-603. PubMed ID: 15523088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
